Minimally Different Cases: DIC vs TTP vs HIT Type 2
Three critically ill patients each present with thrombocytopenia, yet each requires a completely different diagnosis and management pathway. The trap is that the platelet count alone cannot separate them—you must integrate fibrinogen, PT/PTT, the smear (schistocytes), and the clinical context. This review uses three deliberately similar cases—ICU sepsis, motor vehicle accident trauma, and a patient on heparin—to lock in the discriminating features of DIC, TTP, and HIT Type 2.
Case A — ICU Sepsis: DIC
A septic ICU patient has platelets of 45,000, prolonged PT/PTT, and schistocytes on smear. The discriminating finding is a LOW fibrinogen (85) with an elevated D-dimer. DIC is not a primary disease but a complication of an underlying condition (here, sepsis). Systemic activation of coagulation—usually via tissue factor exposure—drives widespread microvascular thrombosis that consumes clotting factors and platelets, followed by secondary fibrinolysis. The result is simultaneous clotting AND bleeding: petechiae, wound oozing, GI bleeding, and multiorgan failure in acute consumptive DIC. Low fibrinogen is the key point that separates DIC from TTP, where fibrinogen is normal. Management centers on treating the underlying cause; supportive measures include platelets if bleeding or very low counts, and FFP or cryoprecipitate for low fibrinogen with bleeding.
Case B — MVA Trauma Context: TTP
This patient has platelets of 38,000 with schistocytes present, but critically, a NORMAL PT/PTT and a NORMAL fibrinogen (320). That combination of microangiopathic hemolysis with normal coagulation studies points to TTP rather than DIC. The defining diagnostic finding is severe ADAMTS13 deficiency (activity <10%) — this alone establishes TTP. Neurologic symptoms (headache, confusion, focal deficits, altered mental status) are common, occurring in roughly half of patients at presentation, but they are part of the classic (and no longer required) pentad and are NOT necessary for diagnosis, so do not wait for them. Because the coagulation cascade is not being consumed, PT/PTT and fibrinogen stay normal—this is exactly what distinguishes TTP from DIC despite both showing schistocytes and thrombocytopenia. The presence of schistocytes reflects mechanical shearing of red cells in the microvasculature. Management is a true hematologic emergency: start emergent plasma exchange (PLEX) urgently based on clinical suspicion, before ADAMTS13 results return, since delay is fatal. Add corticosteroids, and use rituximab and caplacizumab as adjuncts. Do NOT transfuse platelets unless there is life-threatening bleeding, as this may fuel further microvascular thrombosis.
Case C — On Heparin: HIT Type 2
A patient on heparin has platelets of 52,000, a prolonged PTT (aPTT) that is explained by the heparin itself (unfractionated heparin prolongs the aPTT, while the PT/INR stays largely unaffected), a NORMAL fibrinogen (350), and NO schistocytes. The discriminating clue is a >50% drop in platelet count plus a new DVT while on anticoagulation. This is Heparin-Induced Thrombocytopenia Type 2. Heparin binds platelet factor 4 (PF4) forming a neoantigen; IgG antibodies against the PF4-heparin complex activate platelets, which aggregate and release procoagulant microparticles, driving thrombosis while platelets are consumed. It is the paradoxical 'thrombocytopenia' that causes clots, not bleeding—30–50% thrombosis risk if untreated. Timing is classically days 5–10 after heparin initiation, and a >50% platelet fall is characteristic. The absence of schistocytes and a normal fibrinogen separate HIT from both DIC and TTP. Management: stop ALL heparin immediately, send the PF4-heparin antibody test, start a non-heparin anticoagulant such as argatroban, do NOT transfuse platelets (worsens thrombosis), and do NOT start warfarin initially (risk of skin necrosis from faster protein C depletion). Image both legs, since silent DVT is common at diagnosis.
High-yield
- All three cases share thrombocytopenia—the platelet count cannot distinguish them.
- LOW fibrinogen distinguishes DIC from TTP (fibrinogen normal in TTP).
- DIC: low fibrinogen + elevated D-dimer + prolonged PT/PTT + schistocytes.
- TTP: severe ADAMTS13 deficiency (<10%) is the defining diagnostic criterion; schistocytes present but PT/PTT and fibrinogen NORMAL. Neuro symptoms are common but NOT required.
- TTP is a hematologic emergency—start plasma exchange (PLEX) urgently on clinical suspicion before ADAMTS13 returns; add steroids ± rituximab/caplacizumab.
- HIT Type 2: >50% platelet drop + new thrombosis on heparin, day 5–10 timing, NO schistocytes, normal fibrinogen.
- HIT is prothrombotic despite the name 'thrombocytopenia.'
- Unfractionated heparin prolongs the aPTT (PTT), not the PT/INR.
- In HIT: stop heparin, start argatroban, avoid platelet transfusion, avoid initial warfarin.
- Schistocytes are present in DIC and TTP (microangiopathic processes) but ABSENT in HIT.
Pitfalls
- Assuming a low platelet count alone can diagnose the condition—fibrinogen, PT/PTT, and the smear are required to separate them.
- Mistaking TTP for DIC because both have schistocytes—TTP has normal PT/PTT and normal fibrinogen.
- Waiting for the full pentad (including neurologic symptoms) to diagnose TTP—microangiopathic hemolysis plus thrombocytopenia is enough to act, and severe ADAMTS13 deficiency (<10%) confirms it; neuro findings are common but not required.
- Delaying plasma exchange in suspected TTP while waiting for ADAMTS13 results—PLEX is life-saving and must be started on clinical suspicion.
- Believing therapeutic heparin prolongs the PT—unfractionated heparin prolongs the aPTT (PTT); PT/INR is used to monitor warfarin.
- Transfusing platelets in HIT—this can worsen thrombosis.
- Starting warfarin first in HIT—risk of warfarin-induced skin necrosis from protein C depletion.
- Treating HIT as a bleeding disorder when it is actually a prothrombotic state (30–50% clot risk if untreated).
- Forgetting that DIC is a complication of an underlying cause—treating the cause is the most important intervention.
Clinical pearls
- Normal fibrinogen + schistocytes + normal PT/PTT = think TTP, not DIC.
- Severe ADAMTS13 deficiency (<10%) confirms TTP—don't wait for the pentad, and start PLEX before it returns.
- Low fibrinogen + elevated D-dimer in a septic patient = DIC.
- >50% platelet drop on day 5–10 of heparin with new clot = HIT Type 2 until proven otherwise.
- No schistocytes helps push you away from a microangiopathy and toward HIT.
- In HIT, anticoagulate despite low platelets—the danger is clotting, not bleeding.
Frequently asked
How do I tell DIC from TTP when both have thrombocytopenia and schistocytes?
Check the fibrinogen and coagulation studies. DIC shows LOW fibrinogen with prolonged PT/PTT and elevated D-dimer, reflecting factor consumption. TTP shows NORMAL fibrinogen and NORMAL PT/PTT because the coagulation cascade is not being consumed—the diagnosis rests on severe ADAMTS13 deficiency (<10%).
Do I need neurologic symptoms to diagnose TTP?
No. Neurologic findings (headache, confusion, focal deficits, altered mental status) are common—present in roughly half of patients at presentation—but they belong to the classic pentad and are not required for diagnosis. Act on microangiopathic hemolysis plus thrombocytopenia; the defining laboratory criterion is severe ADAMTS13 deficiency (activity <10%).
What is the single most important management step in TTP?
Emergent plasma exchange (PLEX). Because untreated TTP is rapidly fatal, start PLEX urgently based on clinical suspicion—before ADAMTS13 results return. Add corticosteroids, with rituximab and caplacizumab as adjuncts. Avoid platelet transfusion unless there is life-threatening bleeding, as it can worsen microvascular thrombosis.
Why is the PTT prolonged in the heparin patient if it's HIT?
Unfractionated heparin prolongs the aPTT (PTT) as its expected anticoagulant effect; the PT/INR stays largely unaffected and is instead used to monitor warfarin. This prolongation is not from a consumptive coagulopathy. Fibrinogen stays normal in HIT, which is what separates it from DIC. The diagnostic clue for HIT is a >50% platelet drop plus new thrombosis on anticoagulation.
Why don't you see schistocytes in HIT?
HIT is an antibody-mediated platelet activation disorder, not a microangiopathic hemolytic process. DIC and TTP shear red cells in the microvasculature producing schistocytes; HIT does not, so the smear lacks them.
What is the paradox of HIT Type 2?
Despite being called a 'thrombocytopenia,' HIT causes thrombosis, not bleeding. Antibodies against the PF4-heparin complex activate platelets, releasing procoagulant microparticles. Untreated, there is a 30–50% risk of clot, so you must anticoagulate even with a low platelet count.
Why shouldn't you transfuse platelets or start warfarin in HIT?
Platelet transfusion can worsen thrombosis. Warfarin started initially can cause warfarin-induced skin necrosis because protein C is depleted faster than the clotting factors. Instead, stop all heparin and start a non-heparin anticoagulant such as argatroban.
What is the single most important treatment step in DIC?
Treat the underlying cause—DIC is a complication, not a primary disease. Supportive care includes platelets for bleeding or very low counts and FFP or cryoprecipitate for low fibrinogen with bleeding.
Turn this into reasoning you can use on exam day — practice Minimally Different Cases: Distinguishing DIC, TTP, and HIT Type 2 on branching cases where your decisions shape the patient.